Table 1.
Clinical pipelines in RNAi therapeutics
| Company | Disease | Status | Technology |
|---|---|---|---|
| Acuity Pharmaceuticals | Age-related Macular degeneration (AMD) | Phase I Clinical | modified siRNA |
| Alnylam Pharmaceuticals | AMD | Phase I Clinical | direct-siRNA |
| Alnylam Pharmaceuticals | Respiratory Syncytial Virus (RSV) | Phase I Clinical in 2006 | direct-siRNA |
| Alnylam Pharmaceuticals | Spinal Cord Injury | Preclinical | direct-siRNA |
| Alnylam Pharmaceuticals | Parkinson's disease | Preclinical | direct-siRNA |
| Benitec | Hepatitis C | Not available | DNA-direct siRNA |
| Benitec | Human immunodeficiency virus (HIV) | Phase I Clinical in 2005 | Multiple siRNA |
| Intradigm Corporation | Solid Tumour | Preclinical | nanoparticle-siRNA |
| Sirna Therapeutics | Age-related Macular degeneration (AMD) | Phase I Clinical | modified siRNA |
| Sirna Therapeutics | Hepatitis C | Preclinical | modified siRNA |
| Sirna Therapeutics | Asthma | Phase I Clinical in 2006 | systemic/aerosol siRNA |
| Sirna Therapeutics | Huntington's disease | Preclinical | AAV-delivered siRNA |
AAV, Adeno-associated Virus. The corresponding company websites are:www.acuitypharmaceuticals.com; www.alynylam.com; www.benitec.com.au; www.intradigm.com and www.sirna.com.